Human Parainfluenza Virus Type 3
1 clinical trials · Condition
◉ Watch Human Parainfluenza Virus Type 3
| Record | Firm | Date |
|---|---|---|
| Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age (NCT06546423) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-07-12 |
Track Human Parainfluenza Virus Type 3 automatically
Every clearance here is in the API, with alerts when new ones post.